Manufacturer of Controlled Substances; Notice of Application, 49020-49021 [E9-23067]

Download as PDF 49020 Federal Register / Vol. 74, No. 185 / Friday, September 25, 2009 / Notices jlentini on DSKJ8SOYB1PROD with NOTICES Against Women Recovery Act solicitation template. The Department of Justice (DOJ), Office of Justice Programs will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and affected agencies. This proposed information collection was previously published in the Federal Register Volume 74, Number 140, page 36510, on July 23, 2009. Comments are encouraged and will be accepted for thirty days until October 26, 2009. This process is conducted in accordance with 5 CFR 1320.10. If you have additional comments, especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact: Amy Callaghan, (202) 514–9292, Office of Audit, Assessment, and Management, Office of Justice Programs, Department of Justice, 810 Seventh Street, NW., Washington, DC 20531 or Amy.Callaghan@usdoj.gov. Written comments and suggestions from the public and affected parties concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points: —Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; —Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; —Enhance the quality, utility, and clarity of the information to be collected; and —Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses. Overview of this information: (1) Type of information collection: Information in response to the required data elements outlined in the solicitation template for programs VerDate Nov<24>2008 18:52 Sep 24, 2009 Jkt 217001 funded under the American Recovery and Reinvestment Act of 2009. (2) The title of the form/collection: Office of Justice Programs and the Office on Violence Against Women Recovery Act solicitation template. (3) The agency form number, if any, and the applicable component of the Department sponsoring the collection: The form label is OMB No. 1121–0323. The Office of Audit, Assessment, and Management, Office of Justice Programs, U.S. Department of Justice is sponsoring the collection. (4) Affected public who will be asked or required to respond, as well as a brief abstract: State agencies, tribal governments, local governments, colleges and universities, non-profit organizations, for-profit organizations and faith-based organizations. The purpose of the Recovery Act solicitation template is to provide a framework to develop program-specific announcements soliciting applications for funding. A program solicitation outlines the specifics of the funding program; describes requirements for eligibility; instructs an applicant on the necessary components of an application under a specific program (e.g, project activities and timeline, proposed budget); and provides registration dates, due dates, and instructions on how to apply within the designated application system. (5) An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond/reply: It is estimated that information will be collected annually from 250 applicants, representing State agencies, tribal governments, local governments, colleges and universities, non-profit organizations, and for-profit organizations. Annual cost to the respondents is based on the number of hours involved in preparing and submitting a complete application package. Public reporting burden for this collection of information is estimated at up to 30 hours per application. The 30-hour estimate is based on the amount of time to prepare research and evaluation proposals, one of the most time-intensive types of applications solicited by OJP. The estimate of burden hours is based on OJP’s prior experience with the application submission process. (6) An estimate of the total public burden (in hours) associated with the collection: The estimated public burden associated with this collection is 7,500 hours. If additional information is required contact: Ms. Lynn Bryant, Department Clearance Officer, United States Department of Justice, Justice PO 00000 Frm 00120 Fmt 4703 Sfmt 4703 Management Division, Policy and Planning Staff, Suite 1600, 601 D Street, NW., Washington, DC 20530. Dated: September 22, 2009. Lynn Bryant, Department Clearance Officer, PRA, U.S. Department of Justice. [FR Doc. E9–23179 Filed 9–24–09; 8:45 am] BILLING CODE 4410–18–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 16, 2009, Cerilliant Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas 78665–2402, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: Drug Cathinone (1235) .......................... Methcathinone (1237) .................. N–Ethylamphetamine (1475) ........ N,N–Dimethylamphetamine (1480). Aminorex (1585) ........................... 4–Methylaminorex (cis isomer) (1590). Gamma-Hydroxybutyric acid (2010). Methaqualone (2565) ................... Alpha-ethyltryptamine (7249) ....... Lysergic acid diethylamide (7315) 2,5–Dimethoxy-4-(n)propylthiophenethylamine (7348). Marihuana (7360) ......................... Tetrahydrocannabinols (7370) ..... Mescaline (7381) .......................... 3,4,5–Trimethoxyamphetamine (7390). 4–Bromo–2,5– dimethoxyamphetamine (7391). 4–Bromo–2,5– dimethoxyphenethylamine (7392). 4–Methyl-2,5dimethoxyamphetamine (7395). 2,5–Dimethoxyamphetamine (7396). 2,5–Dimethoxy-4ethylamphetamine (7399). 3,4–Methylenedioxyamphetamine (7400). 5–Methoxy-3,4methylenedioxyamphetamine (7401). N–Hydroxy-3,4methylendioxyamphetamine (7402). E:\FR\FM\25SEN1.SGM 25SEN1 Schedule I I I I I I I I I I I I I I I I I I I I I I I Federal Register / Vol. 74, No. 185 / Friday, September 25, 2009 / Notices jlentini on DSKJ8SOYB1PROD with NOTICES Drug Schedule 3,4–Methylendioxy-Nethylamphetamine (7404). 3,4– Methylenedioxymethamphetamine (7405). 4–Methoxyamphetamine (7411) ... Alpha-methyltryptamine (7432) .... Bufotenine (7433) ......................... Diethyltryptamine (7434) .............. Dimethyltryptamine (7435) ........... Psilocybin (7437) .......................... Psilocyn (7438) ............................. 5–Methoxy-N,Ndiisopropyltyptamine (7439). N–Benzylpiperazine (7493) .......... Acetyldihydrocodeine (9051) ........ Benzylmorphine (9052) ................ Codeine-N-oxide (9053) ............... Dihydromorphine (9145) ............... Heroin (9200) ............................... Hydromorphinol (9301) ................. Methyldihydromorphine (9304) ..... Morphine-N-oxide (9307) ............. Normorphine (9313) ..................... Pholcodine (9314) ........................ Acetylmethadol (9601) ................. Allylprodine (9602) ....................... Alphacetylmethadol except levoalphacetylmethadol (9603). Alphameprodine (9604) ................ Alphamethadol (9605) .................. Betacetylmethadol (9607) ............ Betameprodine (9608) .................. Betamethadol (9609) .................... Betaprodine (9611) ....................... Hydroxypethidine (9627) .............. Noracymethadol (9633) ................ Norlevorphanol (9634) .................. Normethadone (9635) .................. Trimeperidine (9646) .................... Phenomorphan (9647) ................. 1–Methyl-4-phenyl-4propionoxypiperidine (9661). Para-Fluorofentanyl (9812) .......... 3–Methylfentanyl (9813) ............... Alpha-Methylfentanyl (9814) ........ Acetyl-alpha-methylfentanyl (9815). Beta-hydroxyfentanyl (9830) ........ Beta-hydroxy-3-methylfentanyl (9831). Alpha-Methylthiofentanyl (9832) ... 3–Methylthiofentanyl (9833) ......... Thiofentanyl (9835) ...................... Amphetamine (1100) .................... Methamphetamine (1105) ............ Lisdexamfetamine (1205) ............. Phenmetrazine (1631) .................. Methylphenidate (1724) ................ Amobarbital (2125) ....................... Pentobarbital (2270) ..................... Secobarbital (2315) ...................... Glutethimide (2550) ...................... Nabilone (7379) ............................ 1–Phenylcyclohexylamine (7460) Phencyclidine (7471) .................... 1– Piperidinocyclohexanecarbonitrile (8603). Alphaprodine (9010) ..................... Cocaine (9041) ............................. Codeine (9050) ............................. Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ VerDate Nov<24>2008 18:52 Sep 24, 2009 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II II II II II II II II II II II II II II II II II II Jkt 217001 Drug Schedule Hydromorphone (9150) ................ Diphenoxylate (9170) ................... Benzoylecgonine (9180) ............... Ethylmorphine (9190) ................... Hydrocodone (9193) ..................... Levomethorphan (9210) ............... Levorphanol (9220) ...................... Isomethadone (9226) ................... Meperidine (9230) ........................ Meperidine intermediate-A (9232) Meperidine intermediate-B (9233) Meperidine intermediate-C (9234) Methadone (9250) ........................ Methadone intermediate (9254) ... Dextropropoxyphene, bulk (nondosage forms) (9273). Morphine (9300) ........................... Thebaine (9333) ........................... Levo-alphacetylmethadol (9648) .. Oxymorphone (9652) ................... Noroxymorphone (9668) .............. Racemethorphan (9732) .............. Alfentanil (9737) ........................... Sufentanil (9740) .......................... Tapentadol (9780) ........................ Fentanyl (9801) ............................ II II II II II II II II II II II II II II II II II II II II II II II II II The company plans to manufacture small quantities of the listed controlled substances to make reference standards which will be distributed to their customers. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than November 24, 2009. Dated: September 17, 2009. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E9–23067 Filed 9–24–09; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF LABOR Employee Benefits Security Administration Proposed Extension of Information Collection; Request for Public Comment; Notice of Special Enrollment ACTION: Notice. SUMMARY: The Department of Labor (Department), as part of its continuing PO 00000 Frm 00121 Fmt 4703 Sfmt 4703 49021 effort to reduce paperwork and respondent burden, conducts a preclearance consultation program to provide the general public and Federal agencies with an opportunity to comment on proposed and continuing collections of information in accordance with the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3506(c)(2)((A)). This program helps to ensure that the data the Department gathers can be provided in the desired format, that the reporting burden on the public (time and financial resources) is minimized, that the public understands the Department’s collection instruments, and that the Department can accurately assess the impact of collection requirements on respondents. Currently, the Employee Benefits Security Administration (EBSA) is soliciting comments concerning the extension of a currently approved collection of information arising from the Department’s regulation at 29 CFR 2590.701–6, which requires a notice of special enrollment to be provided to employees who are offered an initial opportunity to enroll in a group health plan. A copy of the information collection request (ICR) can be obtained by contacting the office shown in the ADDRESSES section of this notice. DATES: Written comments must be submitted to the office shown in the ADDRESSES section of this notice on or before November 24, 2009. ADDRESSES: Interested parties are invited to submit written comments regarding the information collection request and burden estimates to G. Christopher Cosby, Office of Policy and Research, Employee Benefits Security Administration, U.S. Department of Labor, 200 Constitution Avenue, NW., Room N–5718, Washington, DC 20210, (202) 693–8410, FAX (202) 219–4745 (these are not toll-free numbers). Comments may also be submitted electronically to the following Internet e-mail address: ebsa.opr@dol.gov. SUPPLEMENTARY INFORMATION: I. Background Subsection (c) of 29 CFR 2590.701–6 requires group health plans to provide a notice describing the plan’s special enrollment rules to each employee who is offered an initial opportunity to enroll in the group health plan. The special enrollment rules described in the notice of special enrollment generally provide enrollment rights to employees and their dependents in specified circumstances occurring after the employee or dependent initially declines to enroll in the plan. EBSA previously submitted an ICR concerning E:\FR\FM\25SEN1.SGM 25SEN1

Agencies

[Federal Register Volume 74, Number 185 (Friday, September 25, 2009)]
[Notices]
[Pages 49020-49021]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-23067]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on July 16, 2009, Cerilliant 
Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas 78665-2402, 
made application by renewal to the Drug Enforcement Administration 
(DEA) as a bulk manufacturer of the basic classes of controlled 
substances listed in schedules I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Cathinone (1235)...........................  I
Methcathinone (1237).......................  I
N-Ethylamphetamine (1475)..................  I
N,N-Dimethylamphetamine (1480).............  I
Aminorex (1585)............................  I
4-Methylaminorex (cis isomer) (1590).......  I
Gamma-Hydroxybutyric acid (2010)...........  I
Methaqualone (2565)........................  I
Alpha-ethyltryptamine (7249)...............  I
Lysergic acid diethylamide (7315)..........  I
2,5-Dimethoxy-4-(n)-                         I
 propylthiophenethylamine (7348).
Marihuana (7360)...........................  I
Tetrahydrocannabinols (7370)...............  I
Mescaline (7381)...........................  I
3,4,5-Trimethoxyamphetamine (7390).........  I
4-Bromo-2,5-dimethoxyamphetamine (7391)....  I
4-Bromo-2,5-dimethoxyphenethylamine (7392).  I
4-Methyl-2,5-dimethoxyamphetamine (7395)...  I
2,5-Dimethoxyamphetamine (7396)............  I
2,5-Dimethoxy-4-ethylamphetamine (7399)....  I
3,4-Methylenedioxyamphetamine (7400).......  I
5-Methoxy-3,4-methylenedioxyamphetamine      I
 (7401).
N-Hydroxy-3,4-methylendioxyamphetamine       I
 (7402).

[[Page 49021]]

 
3,4-Methylendioxy-N-ethylamphetamine (7404)  I
3,4-Methylenedioxymethamphetamine (7405)...  I
4-Methoxyamphetamine (7411)................  I
Alpha-methyltryptamine (7432)..............  I
Bufotenine (7433)..........................  I
Diethyltryptamine (7434)...................  I
Dimethyltryptamine (7435)..................  I
Psilocybin (7437)..........................  I
Psilocyn (7438)............................  I
5-Methoxy-N,N-diisopropyltyptamine (7439)..  I
N-Benzylpiperazine (7493)..................  I
Acetyldihydrocodeine (9051)................  I
Benzylmorphine (9052)......................  I
Codeine-N-oxide (9053).....................  I
Dihydromorphine (9145).....................  I
Heroin (9200)..............................  I
Hydromorphinol (9301)......................  I
Methyldihydromorphine (9304)...............  I
Morphine-N-oxide (9307)....................  I
Normorphine (9313).........................  I
Pholcodine (9314)..........................  I
Acetylmethadol (9601)......................  I
Allylprodine (9602)........................  I
Alphacetylmethadol except levo-              I
 alphacetylmethadol (9603).
Alphameprodine (9604)......................  I
Alphamethadol (9605).......................  I
Betacetylmethadol (9607)...................  I
Betameprodine (9608).......................  I
Betamethadol (9609)........................  I
Betaprodine (9611).........................  I
Hydroxypethidine (9627)....................  I
Noracymethadol (9633)......................  I
Norlevorphanol (9634)......................  I
Normethadone (9635)........................  I
Trimeperidine (9646).......................  I
Phenomorphan (9647)........................  I
1-Methyl-4-phenyl-4-propionoxypiperidine     I
 (9661).
Para-Fluorofentanyl (9812).................  I
3-Methylfentanyl (9813)....................  I
Alpha-Methylfentanyl (9814)................  I
Acetyl-alpha-methylfentanyl (9815).........  I
Beta-hydroxyfentanyl (9830)................  I
Beta-hydroxy-3-methylfentanyl (9831).......  I
Alpha-Methylthiofentanyl (9832)............  I
3-Methylthiofentanyl (9833)................  I
Thiofentanyl (9835)........................  I
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  II
Lisdexamfetamine (1205)....................  II
Phenmetrazine (1631).......................  II
Methylphenidate (1724).....................  II
Amobarbital (2125).........................  II
Pentobarbital (2270).......................  II
Secobarbital (2315)........................  II
Glutethimide (2550)........................  II
Nabilone (7379)............................  II
1-Phenylcyclohexylamine (7460).............  II
Phencyclidine (7471).......................  II
1-Piperidinocyclohexanecarbonitrile (8603).  II
Alphaprodine (9010)........................  II
Cocaine (9041).............................  II
Codeine (9050).............................  II
Dihydrocodeine (9120)......................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Diphenoxylate (9170).......................  II
Benzoylecgonine (9180).....................  II
Ethylmorphine (9190).......................  II
Hydrocodone (9193).........................  II
Levomethorphan (9210)......................  II
Levorphanol (9220).........................  II
Isomethadone (9226)........................  II
Meperidine (9230)..........................  II
Meperidine intermediate-A (9232)...........  II
Meperidine intermediate-B (9233)...........  II
Meperidine intermediate-C (9234)...........  II
Methadone (9250)...........................  II
Methadone intermediate (9254)..............  II
Dextropropoxyphene, bulk (non-dosage forms)  II
 (9273).
Morphine (9300)............................  II
Thebaine (9333)............................  II
Levo-alphacetylmethadol (9648).............  II
Oxymorphone (9652).........................  II
Noroxymorphone (9668)......................  II
Racemethorphan (9732)......................  II
Alfentanil (9737)..........................  II
Sufentanil (9740)..........................  II
Tapentadol (9780)..........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company plans to manufacture small quantities of the listed 
controlled substances to make reference standards which will be 
distributed to their customers.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such substances, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR 1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than November 24, 2009.

    Dated: September 17, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E9-23067 Filed 9-24-09; 8:45 am]
BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.